Read-Gene

Cancer genetics & prevention · Cancer predisposition

MarketGPW NewConnectSzczecin

Focus / modality

Cancer genetics & prevention

Lead asset

Hereditary-cancer testing

Type

Diagnostics

Indication

Cancer predisposition

Stage

Market

Szczecin

Capital tier

GPW NewConnect

Backing

GPW NewConnect

Overview

Genetic testing and prevention programs for hereditary cancers, built on Prof. Lubiński's oncogenetics research.

What they do

Read-Gene S.A., founded in 2005 and headquartered in Szczecin, commercialises methods for detecting, preventing and treating cancers based on genetic testing. It assesses whether individuals carry inherited predispositions to malignancies and translates that into cancer-prevention programs. The company is closely tied to the International Hereditary Cancer Center (IHCC) at the Pomeranian Medical University.

Lead program & status

Read-Gene's work is built on the oncogenetics research of Prof. Jan Lubiński, who leads the IHCC and serves as the company's president. The IHCC has assembled one of the world's largest hereditary-cancer databanks, reportedly comprising over a million records and DNA samples from roughly 120,000 individuals. Read-Gene's offering centres on hereditary-cancer predisposition testing (such as BRCA and other risk genes) coupled with prevention and surveillance programs. The company is listed on the Warsaw Stock Exchange's NewConnect market under the ticker RDG.

Why it matters

Identifying inherited cancer risk lets at-risk individuals enter intensified screening or preventive care before disease develops. By linking a leading academic oncogenetics center to a commercial vehicle, Read-Gene aims to bring that research-grade hereditary-cancer expertise into routine prevention.

FAQ

Who founded Read-Gene's scientific approach?: Read-Gene is built on the hereditary-cancer research of Prof. Jan Lubiński and the International Hereditary Cancer Center in Szczecin, which he leads.
What does Read-Gene test for?: It focuses on genetic predisposition to hereditary cancers and pairs testing with prevention and surveillance programs.
Is Read-Gene publicly listed?: Yes. Read-Gene trades on the Warsaw Stock Exchange NewConnect market under the ticker RDG.

Company website / source ↗ Open the interactive map →

◢ Boom-cycle briefing

Get ahead of the next biotech boom.

New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.

Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.